- Home
- Products
- Customized ADCs
- CXCR4
- Anti-CXCR4 (Ulocuplumab)-MC-MMAF ADC
Anti-CXCR4 (Ulocuplumab)-MC-MMAF ADC (CAT#: ADC-W-1924)
This ADC product is comprised of an anti-CXCR4 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CXCR4
- Alternative Names
- CXCR4; chemokine (C-X-C motif) receptor 4; chemokine (C X C motif), receptor 4 (fusin); C-X-C chemokine receptor type 4; CD184; D2S201E; fusin; HM89; HSY3RR; LESTR; NPY3R; NPYR; NPYY3R; CXC-R4; CXCR-4; CD184 antigen; SDF-1 receptor; neuropeptide Y receptor Y3; seven transmembrane helix receptor; stromal cell-derived factor 1 receptor; lipopolysaccharide-associated protein 3; seven-transmembrane-segment receptor, spleen; leukocyte-derived seven transmembrane domain receptor; leukocyte-derived seven-transmembrane-domain receptor; FB22; LAP3; LCR1; WHIM; NPYRL;
- Target Entrez Gene ID
- 7852
- Target UniProt ID
- P61073
- Overview
- This gene encodes a CXC chemokine receptor specific for stromal cell-derived factor-1. The protein has 7 transmembrane regions and is located on the cell surface. It acts with the CD4 protein to support HIV entry into cells and is also highly expressed in breast cancer cells. Mutations in this gene have been associated with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
- Overview
- Human Anti-CXCR4 IgG4-kappa antibody, Ulocuplumab
- Generic name
- Ulocuplumab
- Host animal
- Human
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ERBB3 (Duligotumab)-MC-MMAF ADC (CAT#: ADC-W-2242)
- Anti-CD56-SPDB-[3H]DM1 ADC (CAT#: ADC-W-599)
- Anti-MYL (Imciromab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2173)
- Anti-TAG-72 (Minretumomab)-SPDB-DM4 ADC (CAT#: ADC-W-1989)
- Anti-ITGAV-DM4 ADC (CAT#: ADC-W-109)
- Anti-TFPI (Concizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1790)
- Anti-MS4A1 (Ublituximab)-SPDB-DM4 ADC (CAT#: ADC-W-1557)
- Anti-CD40LG (Ruplizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-917)
- Anti-Dabigatran (Idarucizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2413)
- Anti-CD19-Mc-MMAF ADC-5 (CAT#: ADC-W-616)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1924. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-519 | Anti-CXCR4-PEG-S-4FB-dasatinib ADC | PEG-S-4FB linker | dasatinib |
| ADC-W-1926 | Anti-CXCR4 (Ulocuplumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-520 | Anti-CXCR4-dasatinib ADC | disulfide-cleavable linkers | dasatinib |
| ADC-W-1922 | Anti-CXCR4 (Ulocuplumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1923 | Anti-CXCR4 (Ulocuplumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-114 | Anti-CD33-Mc-MMAF ADC-3 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-518 | Anti-TM4SF1-Mc-LP2 ADC-2 | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-452 | Anti-CD70-Mc-MMAF ADC-1 | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2550 | Anti-CD74-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.